何琳,李哲,马艳铃,邓意辉
HE Lin,LI Zhe,MA Yan-ling,DENG Yi-hui(School of Pharmacy

• 1:沈阳药科大学药学院

摘要(Abstract)：

目的制备吉非替尼(gefitinib,GFB)脂质体,建立GFB含量测定方法。方法采用乙二胺四乙酸铵(ammonium ethylenediaminetetraacetate,NH4EDTA)梯度法制备吉非替尼脂质体(gefitinib lipo-some,GFBL),以紫外分光光度法测定GFB的含量,检测波长为350 nm。结果实验条件下所用辅料对GFB的测定无干扰,GFB质量浓度在6.0～14.0 mg.L-1内线性关系良好(r=0.999 8),回收率在100.3%～101.9%内,日内及日间RSD均小于2%(n=3),制得GFBL的平均包封率为78.1%。结论乙二胺四乙酸铵梯度法可用于制备GFBL;紫外分光光度法简便易行,结果准确,可用于GFBL的含量测定。
Objective To prepare gefitinib liposomes and establish a method for determination of gefitinib in the liposomes.Methods Gefitinib liposomes were prepared by ammonium ethylenediaminetetraacetate gradient method.Ultraviolet spectrophotometry was used for analyzing the amount of gefitinib,and the detection wavelength was set at 350 nm.Results Gefitinib had a good linear relation over the range of 6.0-14.0 mg · L-1(r=0.999 8),the intra-day RSD and inter-day RSD were less than 2%,the recovery of gefitinib was in a range of 100.3%-101.9%.The average entrapment efficiency of gefitinib liposomes were 78.1%.Conclusions Ammonium ethylenediaminetetraacetate gradient method can be used to prepare gefitinib liposomes.It is a simple and accurate method to determine the contents of gefitinib in the liposomes by ultraviolet spectrophotometry.

关键词(KeyWords)： 吉非替尼;脂质体;乙二胺四乙酸铵梯度法;紫外分光光度法;含量测定
gefitnib;liposome;ammonium ethylenediaminetetraacetate gradient method;ultraviolet spectrophotometry;content determination

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 何琳,李哲,马艳铃,邓意辉
HE Lin,LI Zhe,MA Yan-ling,DENG Yi-hui(School of Pharmacy

DOI: 10.14066/j.cnki.cn21-1349/r.2012.01.014

参考文献(References)：

• [1]CIARDIELLO F,TORTORA G.A novel approach in the treatment of cancer:targeting the epidermal growth factor receptor[J].Clinical Cancer Research,2001,7(10):2958-2970.
• [2]任晓岚,汪鑫,李志裕,等.表皮生长因子受体(EG-FR)酪氨酸激酶抑制剂的研究进展[J].中国新药杂志,2005,14(7):821-826.
• [3]PAO W,MILLER V A,KRIS M G.‘Targeting’the ep-idermal growth factor receptor tyrosine kinase with ge-fitinib(Iressa(r))in non-small cell lung cancer(NSCLC)[J].Seminars in Cancer Biology,2004,14(1):33-40.
• [4]JANNMAAT M L,GIACCONE G.Small-molecule epi-dermal growth factor receptor tyrosine kinase inhibitors[J].Oncologist,2003,8(18):576-586.
• [5]刘倩琦.抗癌药Iressa[J].药学进展,2002,26(6):374-376.
• [6]MAEDA H,WUA J,SAWAA T,et al.Tumor vascular permeability and the EPR effect in macromolecular therapeutics:a review[J].Journal of Controlled Re-lease,2000,65(1/2):271-284.
• [7]GUBERNATOR J,CHWASTEK G,KORYCINSKA M,et al.The encapsulation of idarubicin within liposomes using the novel EDTA ion gradient method ensures im-proved drug retention in vitro and in vivo[J].Journal of Controlled Release,2010,146(1):68-75.
• [8]黄微崴,李哲,张小飞,等.蔗糖八硫酸酯三乙胺梯度法制备重酒石酸长春瑞滨脂质体[J].中国新药杂志,2010,19(20):1903-1906.
• [9]张玲,黄微崴,王健,等.重酒石酸长春瑞滨脂质体包封率测定方法比较[J].沈阳药科大学学报,2010,27(2):105-109.
• [10]U.S.Food and Drug Administration.Iressa Label[EB/OL].[2011-11-31].http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021399s008l6l.pdf.
• [11]于波涛,张志荣,刘文胜,等.提高脂质体包封率的方法及其研究进展[J].中国医药工业杂志,2002,33(11):564-568.
• [12]吕金玲,赵临襄.苹果酸舒尼替尼(sunitinib malate)[J].中国药物化学杂志,2007,17(3):194.
• [13]陈喆,戴媛媛,汤致强.小分子EGFR酪氨酸激酶抑制剂盐酸埃罗替尼[J].中国新药杂志,2005,14(10):1227-1229.
• [14]周宛屏.空间效应对有机反应活性的影响[J].化学通报,1992,6:51-55.
• [15]王瑞莲,刘成梅,刘伟.脂质体制备方法的研究进展[J].农产品加工:学刊,2007,8:12-14.
• [16]宋阳.盐酸阿霉素脂质体的研究[D].沈阳:沈阳药科大学,2009.
• [17]VLACHY N,JAGODA-CWIKLIK B,VACHA R,et al.Hofmeister series and specific interactions of charged headgroups with aqueous ions[J].Advances in Colloid and Interface Science,2009,146(1/2):42-47.
• [18]邓意辉,宋阳,张玲,等.一种囊泡给药系统及其应用:中国,200910012314.2[P].2009-06-30.